Organization | Harrow Health

Harrow Health Report issue

For profit Phase 3 Phase 4

Founded: San Diego CA United States (1998)

Status: No NME R&D (1998)

Organization Overview

First Clinical Trial

2008

NCT00765700

First Marketed Drug

1998

dexamethasone

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

HARROW EYE | Harrow Inc | Imprimis Pharmaceuticals, Inc.

Active Ingredients

Marketed Drugs (12)

apraclonidine (iopidine) (1987)

chloroprocaine (nesacaine) (2022)

dexamethasone (1962)

fluorometholone (fml) (1986)

moxifloxacin (avelox) (2010)

natamycin (natacyn) (1978)

neomycin (1963)

nepafenac (nevanac) (2005)

polymyxin b sulfate (poly-rx) (1963)

rimexolone (vexol) (1994)

tobramycin (nebcin) (1989)

triamcinolone (kenalog) (2007)

Drugs in Phase 4 Trials (6)

bacitracin (polysporin) (1 trial)

bromfenac (xibrom) (1 trial)

chloroprocaine (nesacaine) (1 trial)

gatifloxacin (Zymar) (1 trial)

prednisolone (hydeltra) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

Drugs in Phase 3 Trials (1)

ketoprofen (orudis) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Pain (Phase 3)

Arteriovenous Fistula (Phase 4)

Cataract (Phase 4)

Fistula (Phase 4)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Soft Tissue Injuries (Phase 3)

Wounds and Injuries (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 7